Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 12, 2010, Pages 1495-1502

  Kuiper, Edith M M ^a   Hansen, Bettina E ^a   Adang, Rob P R ^b   Van Nieuwkerk, Carin M J ^c   Timmer, Robin ^d   Drenth, Joost P H ^e   Spoelstra, Piet ^f   Brouwer, Hans T ^g   Kuyvenhoven, Johan P H ^g   Van Buuren, Henk R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VIECURI MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MEDICAL CENTER LEEUWARDEN   (Netherlands)

^g Medical Center Leeuwarden ^*  (Netherlands)

Author keywords

hepatocellular carcinoma; primary biliary cirrhosis; risk factors; screening

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; CHOLAGOGUES AND CHOLERETICS; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; URSODEOXYCHOLIC ACID;

EID: 78349286333     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834059e7     Document Type: Article

References (21)

1. Kuiper EM, Hansen BE, De Vries RA, Den Ouden-Muller JW,Van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136:1281-1287.
2. Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007; 46:1131-1137.
3. Deutsch M, Papatheodoridis GV, Tzakou A, Hadziyannis SJ. Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2008; 20:5-9.
4. Farinati F, Floreani A, De MN, Fagiuoli S, Naccarato R, Chiaramonte M. Hepatocellular carcinoma in primary biliary cirrhosis. J Hepatol 1994; 21:315-316.
5. Jones DE, Metcalf JV, Collier JD, Bassendine MF, James OF. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26:1138-1142.
6. Nijhawan PK, Therneau TM, Dickson ER, Boynton J, Lindor KD. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 1999; 29:1396-1398.
7. Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001; 96:11 60-1163.
8. Shibuya A, Tanaka K, Miyakawa H, Shibata M, Takatori M, Sekiyama K, et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 2002; 35:1172-1178.
9. Findor J, He XS, Sord J, Terg R, Gershwin ME. Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun Rev 2002; 1:220-225.
10. Floreani A, Baragiotta A, Leone MG, Baldo V, Naccarato R. Primary biliary cirrhosis and hepatitis C virus infection. Am J Gastroenterol 2003; 98:2757-2762. (Pubitemid 38020120)
11. Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008; 48:1149-1156.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
13. Taal BG, Schalm SW, Ten Kate FW, Hermans J, Geertzen RG, Feltkamp BE. Clinical diagnosis of primary biliary cirrhosis: a classification based on major and minor criteria. Hepatogastroenterology 1983; 30:178-182.
14. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol1978; 379:103-112.
15. Van Hoogstraten HJ, Hansen BE,Van Buuren HR,Ten Kate FJ, Van Berge-Henegouwen GP, Schalm SW. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. J Hepatol 1999; 31:256-262.
16. Ter Borg PC, Schalm SW, Hansen BE,Van Buuren HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-year cohort study involving 297 patients. Am J Gastroenterol 2006; 101:2044-2050.
17. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1-7.
18. Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48:871-877.
19. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130:715-720.
20. Suzuki A, Lymp J, Donlinger J, Mendes F, Angulo P, Lindor K. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5:259-264.
21. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430.